3D Medicines (Sichuan) Co., Ltd.
Clinical trials sponsored by 3D Medicines (Sichuan) Co., Ltd., explained in plain language.
3D Medicines (Sichuan) Co., Ltd.
1244
HKEX
A biopharmaceutical company developing oncology and immunology drugs.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for advanced endometrial cancer: immunotherapy combo under study Results expected Dec 2026 (estimated)
- New immunotherapy combo shows promise for Hard-to-Treat cancers Results expected Dec 2026 (estimated)
- New shot shows promise for Hard-to-Treat cancers Results expected Dec 2026 (estimated)
- New immunotherapy shot targets tumors with many mutations Results expected Aug 2027 (estimated)